Trials / Completed
CompletedNCT02807402
Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Romania
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 522 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO) data for the interferon-free regimen of paritaprevir (PTV)/ritonavir (r) + ombitasvir (OBV), + dasabuvir (DSV), +/- ribavirin (RBV) in participants with chronic hepatitis C (CHC) in a real life setting across clinical practice patient populations in Romania.
Conditions
Timeline
- Start date
- 2016-07-14
- Primary completion
- 2017-08-04
- Completion
- 2017-08-04
- First posted
- 2016-06-21
- Last updated
- 2019-01-25
- Results posted
- 2019-01-25
Source: ClinicalTrials.gov record NCT02807402. Inclusion in this directory is not an endorsement.